<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1328</article-id><article-id pub-id-type="doi">10.25208/vdv1328</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАУЧНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Psoriatic erythroderma: comparative patient profile and association with psoriatic arthritis</article-title><trans-title-group xml:lang="ru"><trans-title>Псориатическая эритродермия: сравнительная характеристика пациентов и ассоциация с псориатическим артритом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0662-2682</contrib-id><contrib-id contrib-id-type="scopus">57205267691</contrib-id><contrib-id contrib-id-type="spin">6372-2237</contrib-id><name-alternatives><name xml:lang="en"><surname>Bogdanova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Богданова</surname><given-names>Елена Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>bogdanova@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology</institution></aff><aff><institution xml:lang="ru">Государственный научный центр дерматовенерологии и косметологии</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-10-26" publication-format="electronic"><day>26</day><month>10</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-01-27" publication-format="electronic"><day>27</day><month>01</month><year>2023</year></pub-date><volume>98</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>73</fpage><lpage>80</lpage><history><date date-type="received" iso-8601-date="2022-05-16"><day>16</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-07-25"><day>25</day><month>07</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Bogdanova E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Богданова Е.В.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Bogdanova E.V.</copyright-holder><copyright-holder xml:lang="ru">Богданова Е.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/1328">https://vestnikdv.ru/jour/article/view/1328</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Psoriatic erythroderma is rare and one of the most severe forms of psoriasis characterized by involvement of 80–90% of body surface area.</p> <p><bold>Aims.</bold> To compare clinical and demographic characteristics of patients with psoriasis, depending on presence of psoriatic erythroderma in medical history; to assess the association between psoriatic arthritis and a history of psoriatic erythroderma.</p> <p><bold>Materials and methods.</bold> Patients aged 18 years and older with a duration of psoriasis of &gt;10 years, from the psoriasis patients registry were included.</p> <p>Comparison of continuous quantitative variables was performed using <italic>t</italic>-test or Mann–Whitney <italic>U</italic>-test. The χ<sup>2</sup> test or Fisher's exact test was used to compare qualitative binary variables.</p> <p>The odds ratio of psoriatic arthritis in patients with and without a history of psoriatic erythroderma was calculated, unadjusted and adjusted for other independent variables.</p> <p><bold>Results.</bold> The number of patients included in the analysis was 1,870. A history of psoriatic erythroderma (PE) had 227 (12.1%) of them. There were no significant differences in patient age at inclusion to the registry (47.1 ± 13.1 years vs. 47.7 ± 13.3 years), and prevalence of PE among men and women (12.6% vs. 11. 4%).</p> <p>Higher prevalence of arterial hypertension (47.9% vs 32.7%), angina pectoris (6.4% vs. 1.9%), myocardial infarction (3.2% vs. 1.0%), biliary dyskynesia (14.3% vs. 3.9%), fatty liver (12.2% vs. 7.7%), cholelithiasis (8.6% vs. 3.6%), and toxic liver disease (2.2% vs. 0.5%) among patients with vs without history of PE was found.</p> <p>Psoriatic arthritis was diagnosed in 67.0% patients with a history of psoriatic erythroderma. The odds of having psoriatic arthritis in patients with a history of psoriatic erythroderma were 4 times higher than in patients without erythroderma: 4.043 [2.975–5.493]. When adjusted for sex, age, duration of psoriasis, and body mass index, the odds ratio and statistical significance were maintained: 4.064 [2.939–5.619].</p> <p><bold>Conclusions.</bold> Compared to patients without PE those with a history of psoriatic erythroderma have a greater comorbidity burden: a higher prevalence of cardiovascular diseases, diseases of the liver and biliary tract. A significant association between psoriatic arthritis and a history of PE was established.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Псориатическая эритродермия представляет собой редкую и одну из наиболее тяжелых форм псориаза, характеризующуюся вовлечением 80–90% площади поверхности кожи.</p> <p><bold>Цель исследования.</bold> Сравнить клинико-демографические характеристики пациентов с псориазом в зависимости от наличия псориатической эритродермии в анамнезе; оценить наличие ассоциации между установленным диагнозом псориатического артрита и псориатической эритродермией в анамнезе.</p> <p><bold>Методы.</bold> Анализ данных пациентов в возрасте 18 лет и старше с продолжительностью псориаза 10 лет и более (<italic>n</italic> = 1870), включенных в регистр пациентов с псориазом РОДВК.</p> <p>Сравнение непрерывных количественных переменных осуществляли посредством <italic>t</italic>-критерия или <italic>U</italic>-критерия Манна–Уитни, качественных бинарных переменных — критерия χ<sup>2</sup> или точного критерия Фишера.</p> <p>Проводили расчет отношения шансов наличия псориатического артрита у пациентов с и без псориатической эритродермии в анамнезе, в том числе с поправкой на другие независимые переменные.</p> <p><bold>Результаты.</bold> Псориатическую эритродермию в анамнезе имели 227 (12,1%) пациентов. Отсутствовали значимые различия по возрасту (47,1 ± 13,1 года и 47,7 ± 13,3 года), частоте встречаемости ПЭ среди мужчин и женщин (12,6 и 11,4%).</p> <p>Среди пациентов с ПЭ в анамнезе была выше частота встречаемости артериальной гипертензии (47,9% по сравнению с 32,7%), стенокардии (6,4% по сравнению с 1,9%), инфаркта миокарда (3,2% по сравнению с 1,0%), дискинезии желчевыводящих путей (14,3% по сравнению с 3,9%), жировой дегенерации печени (12,2% по сравнению с 7,7%), желчекаменной болезни (8,6% по сравнению с 3,6%) и токсического поражения печени (2,2% по сравнению с 0,5%).</p> <p>Среди пациентов, имевших ПЭ в анамнезе, диагноз псориатического артрита был установлен 67,0%. Шансы наличия псориатического артрита у пациентов с ПЭ в анамнезе были в 4 раза выше, чем у пациентов без эритродермии: 4,043 [2,975–5,493]. При введении поправок на пол, возраст, продолжительность псориаза и индекс массы тела значение и статистическая значимость отношения шансов сохранялись: 4,064 [2,939–5,619].</p> <p><bold>Заключение.</bold> Для пациентов с ПЭ в анамнезе характерен более отягощенный соматический анамнез: по сравнению с пациентами без ПЭ они имеют более высокую распространенность сердечно-сосудистых заболеваний, патологии печени и желчевыводящих путей. Установлена значимая ассоциация между псориатическим артритом и наличием ПЭ в анамнезе.</p></trans-abstract><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>psoriatic erythroderma</kwd><kwd>psoriatic arthritis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>псориатическая эритродермия</kwd><kwd>псориатический артрит</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Псориаз. Клинические рекомендации Российского общества дерматовенерологов и косметологов. 2020. http://www.cr.minzdrav.gov.ru/schema/234_1. [Psoriasis arthropathic. Psoriatic arthritis. Clinical guidelines of Russian society of dermatovenereologists and cosmetologists and Association of rheumatologists of Russia. 2021. http://www.cr.minzdrav.gov.ru/schema/234_1]</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, et al. National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662. doi: 10.1016/j.jaad.2009.05.048</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21:985–991</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Foss MG, Nyckowski T, Steffes W. Erythrodermic Psoriasis Exacerbated by Bupropion. Cureus. 2021;13(10):e18460. doi: 10.7759/cureus.18460</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Potter KA, Motaparthi K, Schoch JJ. Erythrodermic psoriasis after discontinuation of ixekizumab. JAAD Case Rep. 2017;4(1):22–23. doi: 10.1016/j.jdcr.2017.06.026</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Matos-Pires E, Campos S, Mendes-Bastos P, João A, Fernandes C. Erythrodermic psoriasis induced by bupropion. J Eur Acad Dermatol Venereol. 2017;31(2):e129-e130. doi: 10.1111/jdv.13876</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab. Postepy Dermatol Alergol. 2019;36(4):495–497. doi: 10.5114/ada.2019.87454</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Кубанов А.А., Богданова Е.В. Эпидемиология псориаза в Российской Федерации (по данным регистра). Вестник дерматологии и венерологии. 2022;98(1):33–41. [Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik dermatologii i venerologii. 2022;98(1):33–41 (In Russ.)] doi: 10.25208/vdv1268</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–442. doi: 10.1097/HJH.0b013e32835bcce1</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:12-29. doi: 10.1111/jdv.12163</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–157. doi: 10.1111/j.1365-2796.2010.02310.x</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. doi: 10.1161/JAHA.113.000062</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Yamazaki F, Takehana K, Tanaka A, Son Y, Ozaki Y, Tanizaki H. Relationship between Psoriasis and Prevalence of Cardiovascular Disease in 88 Japanese Patients. J Clin Med. 2021;10(16):3640. doi: 10.3390/jcm10163640</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi: 10.1038/nutd.2012.26</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. doi: 10.1001/2013.jamadermatol.406</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martinez-Camblor P, Maldonado-Seral C, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783–793. doi: 10.1111/bjd.12473</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi: 10.1016/j.jaad.2012.08.015</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital Dermatol Venereol. 2016;151(6):663–677.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. doi: 10.1371/journal.pone.0181039</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol Ther. 2021;8(4):1519–1534. doi: 10.1007/s40744-021-00378-w</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Liu P, Kuang Y, Ye L, Peng C, Chen W, Shen M, et al. Predicting the Risk of Psoriatic Arthritis in Plaque Psoriasis Patients: Development and Assessment of a New Predictive Nomogram. Front Immunol. 2022;12:740968. doi: 10.3389/fimmu.2021.740968</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ogdie A, Eder L. The need for strategies to address obesity and psoriatic arthritis prevention in psoriasis. Br J Dermatol. 2020;182(3):523–524. doi: 10.1111/bjd.18595</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Chen Z, Wang Y, Lan X, Yang M, Ding L, Li G, et al. Nomogram for accurate and quantitative prediction of the risk of psoriatic arthritis in Chinese adult patients with moderate and severe plaque psoriasis. Eur J Dermatol. 2021. doi: 10.1684/ejd.2021.4095</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Green A, Shaddick G, Charlton R, Snowball J, Nightingale A, Smith C, et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol. 2020;182(3):714–720. doi: 10.1111/bjd.18227</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2021;84(3):701–711. doi: 10.1016/j.jaad.2020.08.060</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915–923. doi: 10.1002/art.39494</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153–166. doi: 10.1038/s41584-019-0175-0</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Кубанов А.А., Богданова Е.В. Что такое регистры пациентов и зачем они нужны (на примере регистров пациентов с псориазом). Вестник РАМН. 2021;76(2):177–186. doi: https://doi.org/10/15690/vramn1454 [Kubanov AA, Bogdanova EV. What Are Patient Registries And Why Are They Needed (Through a Number of Examples of Psoriasis Registries). Annals of the Russian Academy of Medical Sciences. 2021;76(2):177–186 (In Russ.)] doi: https://doi.org/10/15690/vramn1454</mixed-citation></ref></ref-list></back></article>
